TOP-5 Analyst Price Targets as of 10/30/25
Reading Time: 3 minutes
A xoGen [US05463X1063] Citizens JMP reaffirms Buy rating and raises the price target from $26 to $34 (53% upside potential) The positive assessment is based on the recent quarterly results, in which AxoGen achieved a record revenue of $60.1 million. According to the analyst, this marks the second-best revenue growth in the last four years, underscoring the company's momentum. AxoGen specializes in developing innovative solutions for the repair and protection of peripheral nerves. The product Avance, for which a biologics approval application...
Read this article now with a free account.
Your benefits:
- Every month, you can read 5 articles from the premium section for free.
- Monthly 2 trial issues of the Trader newspaper for free.
- Create a personal watchlist with an overview of news about your stock.
